Tristar Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 17-11-2024
- Paid Up Capital ₹ 7.33 Cr
as on 17-11-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 82.47 Cr
as on 17-11-2024
- Satisfied Charges ₹ 104.40 Cr
as on 17-11-2024
- Revenue -8.89%
(FY 2023)
- Profit 16496.55%
(FY 2023)
- Ebitda 27.60%
(FY 2023)
- Net Worth 11.61%
(FY 2023)
- Total Assets -2.51%
(FY 2023)
About Tristar Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 7.33 Cr.
The company currently has active open charges totaling ₹82.47 Cr. The company has closed loans amounting to ₹104.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Arun Premchand and Arpit Arun serve as directors at the Company.
- CIN/LLPIN
U85110MH2006PTC159834
- Company No.
159834
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tristar Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Premchand  | Director | 17-Feb-2006 | Current |
| Arpit Arun | Director | 01-Mar-2012 | Current |
Financial Performance of Tristar Lifesciences.
Tristar Lifesciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.89% decrease. The company also saw a substantial improvement in profitability, with a 16496.55% increase in profit. The company's net worth Soared by an impressive increase of 11.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tristar Lifesciences?
In 2023, Tristar Lifesciences had a promoter holding of 98.22% and a public holding of 1.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 29 Jul 2024 | ₹2.00 Cr | Open |
Indian Bank Creation Date: 22 May 2022 | ₹5.67 Cr | Open |
Indian Bank Creation Date: 22 May 2022 | ₹74.80 Cr | Open |
How Many Employees Work at Tristar Lifesciences?
Tristar Lifesciences has a workforce of 34 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tristar Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tristar Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
